Matthew Campbell, MD, provides an overview of metastatic urothelial cancer (mUC) and PD-1/PD-L1 blockade as the new standard in second line therapy.  In addition, Dr. Campbell discuss the ongoing and future exploration in UC.

Biography:
Matthew Campbell Assistant Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Additional reading:
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

A phase II study of atezolizumab with or without bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma patients 

Systemic Immunotherapy Bladder Cancer.. Get Ready